The first patient has enrolled for the first new clinical study for EXPEDITE (Evaluate a NeXt Generation PortablE Diagnostic Platform for Determination and Immediate Triage of Emergency Large Vessel Stroke), according to Neural Analytics. According to neural Analytics, “This clinical study is a phase I clinical study at Erlanger Health System in Chattanooga, Tennessee that will evaluate the company’s portable monitoring platform for patients suffering an acute ischemic stroke.”

Although stroke research has advanced, there is no trustworthy diagnostic and monitoring method available for emergency room first responders and doctors to use in the clinical community. The stroke assessments that do exist are not highly accurate. Due to this, patients remain in treatment for longer periods of time, increasing their medical costs.

This clinical study will examine Neural analytics’ technology for examining strokes and to test whether early emergency room examination can result in a better outcome for the patient.

According to Neural Analytics, “The creation of a convenient, quantitative assessment system for the early detection of stroke is one of our most critical needs. We believe such a diagnostic tool will transform global patient management when it becomes available,” said Dr. Tom Devlin, Medical Director of Erlanger’s Southeast Regional Stroke Center and Principal Investigator of the study. “We are thrilled to be the first site in the world to begin evaluation of this promising technology, which uses ultrasound to rapidly assess blood flow in the brain and may help healthcare professionals determine if a patient is suffering a stroke.”

The clinical study will consist of 150 patients who may be having a large Vessel Occlusion (LVO) Stroke, studying how quick and reliable the method is in an emergency environment.